Drug profile · INN
glibenclamide
DAONIL
glibenclamide (DAONIL) is a sulfonylurea receptor 1, kir6.2 blocker. Associated with Sanofi-aventis Healthcare Pty Ltd.
EMA: approved TGA: approved Alimentary tract and metabolism (A10) A10BB01
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — glibenclamide
- Class
- Alimentary tract and metabolism (A10)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
glibenclamide (DAONIL) is a sulfonylurea receptor 1, kir6.2 blocker. Associated with Sanofi-aventis Healthcare Pty Ltd.
Key facts
INN glibenclamide
Brand DAONIL
Mechanism Sulfonylurea receptor 1, Kir6.2 blocker
Target Sulfonylurea receptor 1, Kir6.2
Therapeutic class Alimentary tract and metabolism (A10)
ATC code A10BB01
Originator Sanofi-aventis Healthcare Pty Ltd
Mechanism of action
Sulfonylurea receptor 1, Kir6.2 blocker
Primary target: Sulfonylurea receptor 1, Kir6.2
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is glibenclamide?
glibenclamide (DAONIL) is a sulfonylurea receptor 1, kir6.2 blocker. Associated with Sanofi-aventis Healthcare Pty Ltd.
What is the brand name for glibenclamide?
DAONIL is a marketed brand name for glibenclamide. Check FDA Drugs@FDA for the current US label holder and prescribing information.